Article

Pharmacological block of the slow component of the outward delayed rectifier current (I(Ks)) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration.

Department of Internal Medicine, Faculty of Medicine, University of Szeged, Szeged, Hungary.
British Journal of Pharmacology (Impact Factor: 4.99). 01/2001; 132(1):101-10. DOI: 10.1038/sj.bjp.0703777
Source: PubMed

ABSTRACT 1. The effects of I(Ks) block by chromanol 293B and L-735,821 on rabbit QT-interval, action potential duration (APD), and membrane current were compared to those of E-4031, a recognized I(Kr) blocker. Measurements were made in rabbit Langendorff-perfused whole hearts, isolated papillary muscle, and single isolated ventricular myocytes. 2. Neither chromanol 293B (10 microM) nor L-735,821 (100 nM) had a significant effect on QTc interval in Langendorff-perfused hearts. E-4031 (100 nM), on the other hand, significantly increased QTc interval (35.6+/-3.9%, n=8, P<0.05). 3. Similarly both chromanol 293B (10 microM) and L-735,821 (100 nM) produced little increase in papillary muscle APD (less than 7%) while pacing at cycle lengths between 300 and 5000 ms. In contrast, E-4031 (100 nM) markedly increased (30 - 60%) APD in a reverse frequency-dependent manner. 4. In ventricular myocytes, the same concentrations of chromanol 293B (10 microM), L-735,821 (100 nM) and E-4031 (1 microM) markedly or totally blocked I(Ks) and I(Kr), respectively. 5. I(Ks) tail currents activated slowly (at +30 mV, tau=888.1+/-48.2 ms, n=21) and deactivated rapidly (at -40 mV, tau=157.1+/-4.7 ms, n=22), while I(Kr) tail currents activated rapidly (at +30 mV, tau=35.5+/-3.1 ms, n=26) and deactivated slowly (at -40 mV, tau(1)=641.5+/-29.0 ms, tau(2)=6531+/-343, n=35). I(Kr) was estimated to contribute substantially more to total current density during normal ventricular muscle action potentials (i.e., after a 150 ms square pulse to +30 mV) than does I(Ks). 6. These findings indicate that block of I(Ks) is not likely to provide antiarrhythmic benefit by lengthening normal ventricular muscle QTc, APD, and refractoriness over a wide range of frequencies.

Download full-text

Full-text

Available from: Norbert Jost, Jun 23, 2015
0 Followers
 · 
89 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activators of the slow delayed rectifier K(+) current (IKs) have been suggested as promising tools for suppressing ventricular arrhythmias due to prolongation of repolarization. Recently, L-364,373 (R-L3) was nominated to activate IKs in myocytes from several species; however, in some studies, it failed to activate IKs. One later study suggested opposite modulating effects from the R-L3 enantiomers as a possible explanation for this discrepancy. Therefore, we analyzed the effect of the RL-3 enantiomers on IKs in ventricular mammalian myocytes, by applying standard microelectrode and whole-cell patch-clamp techniques at 37 °C. We synthesized 2 substances, ZS_1270B (right) and ZS_1271B (left), the 2 enantiomers of R-L3. In rabbit myocytes, ZS_1270B enhanced the IKs tail current by approximately 30%, whereas ZS_1271B reduced IKs tails by 45%. In guinea pig right ventricular preparations, ZS_1270B shortened APD90 (action potential duration measured at 90% repolarization) by 12%, whereas ZS_1271B lengthened it by approximately 15%. We concluded that R-L3 enantiomers in the same concentration range indeed have opposite modulating effects on IKs, which may explain why the racemic drug R-L3 previously failed to activate IKs. ZS_1270B is a potent IKs activator, therefore, this substance is appropriate to test whether IKs activators are ideal tools to suppress ventricular arrhythmias originating from prolongation of action potentials.
    Canadian Journal of Physiology and Pharmacology 08/2013; 91(8):586-92. DOI:10.1139/cjpp-2012-0407 · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Activators of slow delayed rectifier K<sup>+</sup> current (I<sub>Ks</sub>) have been suggested as promising tools to suppress ventricular arrhythmias due to prolongation of repolarization. Recently, L-364,373 (R-L3), was nominated to activate I<sub>Ks</sub> in myocytes from several species, however, in some studies failed to activate I<sub>Ks</sub>. One later study suggested the adverse modulating effects of the R-L3 enantiomers as possible explanation for this discrepancy. Therefore, we have analysed the effect of the RL-3 enantiomers on I<sub>Ks</sub> in ventricular mammalian myocytes, by applying standard microelectrode and whole-cell patch clamp techniques at 37 C. We synthesised two substances, ZS_1270B (right) and ZS_1271B (left), the two enantiomers of R-L3. In rabbit myocytes ZS_1270B enhanced I<sub>Ks</sub> tail current by about 30%, while ZS_1271B reduced I<sub>Ks</sub> tails by 45%. In guinea pig right ventricular preparations ZS_1270B shortened APD<sub>90</sub> by 12%, while ZS_1271B, conversely lengthened it approximately 15%. We concluded that R-L3 enantiomers indeed have adverse modulating effects on I<sub>Ks</sub> in the same concentration range, which may explain why the racemic drug R-L3 previously failed to activate I<sub>Ks</sub>. ZS_1270B is a potent I<sub>Ks</sub> activator: therefore, this substance is adequate to test whether I<sub>Ks</sub> activators are indeed ideal tools to suppress ventricular arrhythmias originating from prolongation of action potentials.
    Canadian Journal of Physiology and Pharmacology 01/2013; epub. · 1.55 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inhibition of cardiac late Na(+) current (late I(Na)) is a strategy to suppress arrhythmias and sodium-dependent calcium overload associated with myocardial ischemia and heart failure. Current inhibitors of this current are unselective and can be proarrhythmic. This study introduces GS967 (6-(4-(trifluoromethoxy)phenyl)-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine), a potent and selective inhibitor of late I(Na), and demonstrates its effectiveness to suppress ventricular arrhythmias. The effects of GS967 on rabbit ventricular myocyte ion channel currents and action potentials were determined. Anti-arrhythmic actions of GS967 were characterized in ex vivo and in vivo rabbit models of reduced repolarization reserve and ischemia. GS967 inhibited Anemonia sulcata toxin II (ATX-II)-induced late I(Na) in ventricular myocytes and isolated hearts with IC(50) values of 0.13 and 0.21 micromolar, respectively. Reduction of peak I(Na) by GS967 was minimal at a holding potential of -120 mV but increased at -80 mV. GS967 did not prolong action potential duration or the QRS interval. GS967 prevented and reversed proarrhythmic effects (afterdepolarizations, torsades de pointes) of the late I(Na) enhancer ATX-II and the I(Kr) inhibitor E-4031 in isolated ventricular myocytes and hearts. GS967 significantly attenuated the proarrhythmic effects of methoxamine+clofilium, and suppressed ischemia-induced arrhythmias. GS967 was more potent and effective to reduce late I(Na) and arrhythmias than either flecainide or ranolazine. Results of all studies and assays of binding and activity of GS967 at numerous receptors, transporters and enzymes indicated that GS967 selectively inhibited late I(Na). In summary, GS967 selectively suppressed late I(Na) and prevented and/or reduced the incidence of experimentally-induced arrhythmias in rabbit myocytes and hearts.
    Journal of Pharmacology and Experimental Therapeutics 09/2012; 344(1). DOI:10.1124/jpet.112.198887 · 3.86 Impact Factor